Ursodeoxycholic Acid Therapy in Cystic Fibrosis—Associated Liver Disease: A Dose–Response Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Previous studies from our groups have demonstrated improvements in biochemical markers of liver function when cystic fibrosis patients with associated liver disease were administered oral ursodeoxycholic acid. The magnitude of the response was somewhat less than that found when comparable doses (10 to 15 mg/kg body wt/day) of ursodeoxycholic acid are given to other liver disease patients; this may be explained by the bile acid malabsorption that is characteristic of the disease. For this reason a dose–response study was carried out in nine cystic fibrosis patients with liver disease to establish whether improved efficacy could be obtained with higher doses. Ursodeoxycholic acid in doses of 5, 10 and 15 mg/kg body wt/day was given orally for consecutive 2–mo periods in a replicated Latinsquare design. After this, all patients received 20 mg/kg body wt/day. Liver function, individual serum bile acids and biliary bile acid composition were determined at entry and at the end of each treatment period. Our data demonstrate that the magnitude of the biochemical improvement in serum liver enzymes was significantly greater with higher doses of ursodeoxycholic acid; at 20 mg/kg body wt/day it was similar to that reported for patients with other liver diseases administered lower doses. Biliary ursodeoxycholic acid enrichment increased with increasing doses, attaining 42% ± 6% of the total biliary bile acids with the highest dose. Fasting serum ursodeoxycholic acid concentrations increased during ursodeoxycholic acid administration but were variable and correlated poorly with the dose of ursodeoxycholic acid administered, whereas no correlation was found between serum ursodeoxycholic acid concentration and the proportion of ursodeoxycholic acid in bile. Our data indicate a need for doses of ursodeoxycholic acid of 20 mg/kg body wt/day or greater to obtain optimal improvement in biochemical indices of liver function and biliary ursodeoxycholic acid enrichment in cystic fibrosis patients with associated liver disease. (HEPATOLOGY 1992;16:924-930.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Ursodeoxycholic acid for primary sclerosing cholangitis
Chazouillères, O., Poupon, R., Capron, J.-P., Metman, E.-H., Dhumeaux, D., Amouretti, M., Couzigou, P., Labayle, D., & Trinchet, J.-C. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90281-u · Cited by 165
Cited by
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Yankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H., & Rodman, D. (2004) · Chest · doi:10.1378/chest.125.1_suppl.1s · Cited by 579
Zaroff, J. G., Rosengard, B. R., Armstrong, W. F., Babcock, W. D., D’Alessandro, A., Dec, G. W., Edwards, N. M., Higgins, R. S., Jeevanandum, V., Kauffman, M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000025587.40373.75 · Cited by 495
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 432
Self-citation
Metadata
- Authors
- Colombo, C., Crosignani, A., Assaisso, M., Battezzati, P. M., Podda, M., Giunta, A., Zimmer-Nechemias, L., & Setchell, K. D. R.
- Venue
- Hepatology
- Published
- 1992-10
- Volume
- 16
- Issue
- 4
- Pages
- 924-930
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2021644202
- Cited by
- 129
- References
- 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ursodeoxycholic Acid Therapy in Cystic Fibrosis—Associated Liver Disease: A Dose–Response Study. https://app.cochat.ai/papers/10.1002/hep.1840160412
- The paper
- Colombo, C., Crosignani, A., Assaisso, M., Battezzati, P. M., Podda, M., Giunta, A., Zimmer-Nechemias, L., & Setchell, K. D. R. (1992). Ursodeoxycholic Acid Therapy in Cystic Fibrosis—Associated Liver Disease: A Dose–Response Study. Hepatology. https://doi.org/10.1002/hep.1840160412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.